LONDON – One of the academic lynchpins of UK biotech, John Martin, has attracted £15.5 million (US$24.9 million) in private equity for Magnus Life Sciences Ltd., a start-up shaped to overcome his frustrations at current shortcomings and gaps in the process of translating research from lab to bedside.